Overall, these clinical data from NSCLC and melanoma, while limited by lack of ICB treatment and tumor type, respectively, support our preclinical studies demonstrating an increase in ATX after an initial response and subsequent resistance to anti–PD-1 treatment. This evidence concerns the gene ENPP2 and neoplasm.